(AIM: SAR)

04 December 2014

SAREUM HOLDINGS PLC

(“Sareum” or the “Company”)

Chinese Patent Grant for Sareum’s Kinase Inhibitors

Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the Company has been notified by the China Patent & Trademark Office that a patent has been granted for one of Sareum’s key drug discovery inventions.

This patent*, which relates to compounds that inhibit or modulate the activity of kinase enzymes, forms the basis of Sareum’s SKIL® drug discovery platform. The granting of this patent means that Sareum has approved patent protection in China for its SKIL platform and many of its drug discovery programmes. Similar patents have previously been granted to Sareum in the USA and Japan, and the Company expects to receive further protection, including in Europe, in due course.

SKIL (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

* Patent No. ZL200880024256.9

Sareum’s CSO, Dr John Reader, commented: “The granting of this patent in China strengthens our patent portfolio, and enhances our negotiating position with potential licensing partners”.

Enquiries:

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

Sanlam Securities UK Limited (Nomad)

Simon Clements / James Thomas

020 7628 2200

Hybridan LLP (Broker)

 

Claire Noyce / William Lynne

0203 713 4581/ 4582

The Communications Portfolio (Media enquiries)

 

Ariane Comstive
Ariane.comstive@communications-portfolio.co.uk

020 7536 2028

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers.  Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk